View Older Stories View More Recent Stories
-
Biogen and Stoke present 3-year zorevunersen data for Dravet syndrome
-
Biogen (BIIB) PT Lowered to $217 at RBC Capital
-
Eisai and Biogen launch at-home injection option for alzheimer's drug
-
Jefferies sees 'an attractive setup' in this large biotech stock
-
Jefferies Starts Biogen (BIIB) at Buy
-
Eisai and Biogen receive approval for LEQEMBI in Australia
-
FDA requests technical updates for Biogen's high dose nusinersen application
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Biogen gets European approval for postpartum depression treatment
-
Canaccord Genuity Reiterates Buy Rating on Biogen (BIIB)
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
FDA approves Eisai's LEQEMBI IQLIK for Alzheimer's maintenance treatment
-
Biogen and Stoke present three-year zorevunersen data for Dravet syndrome
-
Stoke Therapeutics and Biogen present 3-year zorevunersen data for Dravet
-
Stoke Therapeutics and Biogen to present zorevunersen data at epilepsy congress
-
Biogen (BIIB) PT Raised to $118 at Piper Sandler
-
U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
-
Biogen (BIIB) PT Raised to $194 at H.C. Wainwright
-
Biogen (BIIB) PT Lowered to $144 at Morgan Stanley
-
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB)
-
Biogen (BIIB) Tops Q2 EPS by $1.48, Beats on Revenue; Offers Guidance
-
Eisai and Biogen present two-year LEQEMBI real-world study results
-
Eisai and Biogen present data on subcutaneous LEQEMBI maintenance dosing
-
ZURZUVAE receives positive CHMP opinion for postpartum depression treatment
-
Truist Securities Starts Biogen (BIIB) at Hold
-
Biogen plans $2 billion manufacturing investment in North Carolina
-
U.S. large biotech stocks Q2 earnings preview
-
Biogen (BIIB) PT Raised to $130 at UBS
-
JPMorgan Reiterates Neutral Rating on Biogen (BIIB)
-
RBC Capital on Biogen (BIIB): 'Long-Term Vision Coming Together'
-
Biogen (BIIB) sees $0.26 per share charge in Q2
-
Biogen (BIIB) Updates Q2 Guidance
-
These 30 global stocks offer tactical and structural upside, says RBC
-
RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimer’s market
-
Biogen (BIIB) Initiates Phase 3 Study of Felzartamab
-
RBC: "How LLY Could Blaze a Trail and BIIB Could Pull AHEAD In The Large, Overlooked Pre-Sx AD Mkt"
-
H.C. Wainwright on Biogen (BIIB): 'Salanersen can help cement Biogen’s leadership in SMA'
-
Biogen (BIIB) to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
-
Biogen (BIIB) Initiates Phase 3 Pediatric Study of Omaveloxolone
-
UBS Reiterates Neutral Rating on Biogen (BIIB)
-
Jefferies: 'We highlight multiple de-risked or commercial-stage names that we think have promising M&A potential'
-
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
-
Stifel weighs in on Biogen (BIIB) following R&D event
-
Entrada Therapeutics (TRDA) Appoints Maha Radhakrishnan to its Board
-
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
-
Biogen (BIIB) PT Lowered to $187 at H.C. Wainwright
-
Biogen (BIIB) PT Lowered to $220 at Canaccord Genuity
-
Stifel Reiterates Hold Rating on Biogen (BIIB) Following EPS
-
Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
-
Biogen (BIIB) PT Lowered to $199 at Truist Securities
